In a comparative effectiveness research study published in JAMA, cladribine (Mavenclad; EMD Serono) outperformed sphingosine-1-phosphate receptor modulators (S1Ps) in reducing disability progression over a 25-month period in treatment-naive…
Cladribine More Effective Than S1P Receptor Modulators in Treating Relapsing-Remitting MS, Study Shows | NeurologyLive
